A significant amount of research and preclinical development is being conducted on developing monoclonal antibodies to target surface ROR1 in CLL and other malignancies (Baskar et al., 2012; Choi et al., 2015; Qi et al., 2018). The gene discussed is ROR1; the disease is B-cell chronic lymphocytic leukemia.